Novavax Stock: Bull vs. Bear
Are you the kind of person who sees the glass as half-full or half-empty? The answer will probably determine how you look at Novavax (NASDAQ: NVAX).
The stock has delivered a return of more than 70% year to date. Many investors would think that's great. However, others would look at the opportunities Novavax has failed to capitalize on because of delays in filing with regulators for authorizations for its COVID-19 vaccine. Prior to when those setbacks began, the stock was up by nearly 190% for the year.
But is Novavax stock a buy now? Again, there are different ways to look at the question. Here are the bull and bear arguments for this vaccine stock.
Source Fool.com
